Roquette Commits to BioPharma Market

Roquette offers materials for cell culture and biologic drug formulations. The products are low endotoxin multicompendial materials

BPI Contributor

March 13, 2017

1 Min Read
Roquette Commits to BioPharma Market

Roquette, a global leader in innovative plant-based pharmaceutical ingredients, announces its commitment to provide new product offerings to address the growing demand for excipients and raw materials for the biopharmaceutical market.

New product offerings are low endotoxin, multi-compendial grade materials for cell culture and biologic drug formulations. These products extend Roquette’s commitment to helping customers save and sustain patient’s lives.

“As a long-time leader in excipients and active ingredients for the pharmaceutical market, Roquette is proud to be part of this major therapeutic progress and is excited to introduce several new products in the U.S., Europe and Asia,” said Paul Smaltz, vice president of Global Business Unit Pharma.

“We have three new brands coming to the market under the names LYCADEX® BioPharma dextrose, PEARLITOL® BioPharma mannitol and NEOSORB® BioPharma sorbitol with a plan to continue adding to the portfolio,” said Kelsey Achenbach, Pharma marketing director. “Customers now have an alternative option with a partner who is an established manufacturer and has sole custody of the supply chain when it comes to materials for biopharmaceuticals.”

This investment reaffirms the company’s strategic initiatives to develop specialties for pharma, food, nutrition and health markets to accelerate global growth. The BioPharma market launch addresses the growing customer demand for biologic drugs worldwide. These protein-based drugs can be game-changing by having the ability to put rheumatoid arthritis into remission and transform many cancers into treatable conditions.

You May Also Like